Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
18% of US respondents reported taking prescription drugs for weight loss in 2025, up from 10% in 2024 Source: Euromonitors Voice of the Consumer: Health and Nutrition Survey, fielded February 2024 Legacy weight loss brands turn their attention towards GLP-1 consumers Heritage weight loss companies are shifting focus to accommodate the GLP-1 consumer
1 Some have cited concern over confounding variables including the fact that patients with diabetes are at an increased risk of acute pancreatitis regardless of treatment choice
But weight loss alone does not capture the full scope of the 12-month transformation
That is what actually works
The Umbrella Labs retatrutide program is structured to reduce those risks through specification forward listing fields and stable catalog references that are easy to incorporate into laboratory recordkeeping
Currently, approximately 40 million patients in the US have insurance coverage for Wegovy--30 million via commercial health insurance, and the remaining through Medicaid
